

Supplementary Table 1. Relative risks of adiponectin for predicting renal complications according to CKD stages (1 and 2)

Variable	Cases, no./total no.	OR	95% CI	p value
CKD stage 1 (eGFR \geq 90 mL/min/1.73 m ²) (n = 62)				
Unadjusted OR				
Nephropathy	19/62	1.225	0.963–1.559	0.098
Dialysis	3/62	1.054	1.008–1.103	0.021
Adjusted OR ^a				
Dialysis	3/62	1.065	1.006–1.128	0.030
CKD stage 2 (60 \leq eGFR < 90 mL/min/1.73 m ²) (n = 58)				
Nephropathy	16/58	0.953	0.793–1.146	0.611
Dialysis	2/58	1.041	0.996–1.088	0.077

CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.

^aThe related risk of adiponectin ($\mu\text{g}/\text{min} \times 10$) was adjusted for sex (male/female), age (yr), eGFR (mL/min/1.73 m²), urine albumin to creatinine ratio ($\mu\text{g}/\text{mL}$), urine protein to creatinine ratio (mg/mg $\times 100$), hypertension (yes/no).